5:40 PM
 | 
Mar 01, 2013
 |  BC Extra  |  Company News

IQWiG says Pixuvri provides 'no additional benefit'

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) said in a preliminary benefit assessment that cancer drug Pixuvri pixantrone from Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC) provides "no additional benefit" over patient-individualized care because the company did not submit...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >